WOBURN, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vertero Therapeutics, a clinical-stage biotechnology company breaking barriers in neurodegenerative disease treatment, today announced that it has ...
It wouldn’t be a new Final Fantasy XIV expansion if there wasn’t some kind of server issues afoot. Granted so far Shadowbringers launch has been smooth compared to other previous launches. There ...
VT-5006 is a first-in-class small molecule designed to precisely engage a validated peripheral target to delay onset and slow progression of Parkinson’s disease WOBURN, Mass., Nov. 24, 2025 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results